Part 3: Aggressive B-Cell Non-Hodgkin Lymphoma

Leena Varkey Maramattom, MD

Mazie Froedtert Willms & Sue Froedtert Cancer Fellow, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Timothy S. Fenske, MD

Associate Professor of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Question 3

Questions 1–3 are based on the following clinical scenario:
A 62-year-old man has recently been diagnosed with stage IV-A diffuse large B-cell lymphoma (DLBCL).

The patient achieves a complete response with first-line therapy, but then develops a relapse 8 months later. What would be the standard of care in this situation?

  •  R-CHOP-14
  •  R-CHOP-21
  •  Radiation therapy to current but not prior sites of disease
  •  Rituximab as a single agent
  •  Platinum-based therapy chemotherapy, followed by high-dose therapy and
    autologous stem cell transplantation

Updated 7/05/2011 • jdw | Copyright ©2013 Turner White Communications